Stargardt Disease (STGD1) Clinical Trials and Treatments

Stargardt disease is caused by biallelic mutations in the ABCA4 gene, which encodes a retina-specific ATP-binding cassette transporter. This protein normally removes toxic byproducts of the visual cycle, particularly N-retinylidene-phosphatidylethanolamine (NRPE), from photoreceptor disc membranes. When ABCA4 is defective, these byproducts accumulate and are converted to lipofuscin, particularly the toxic bisretinoid A2E, which is deposited in retinal pigment epithelium (RPE) cells.

The most common symptoms of Stargardt Disease include Progressive loss of central vision (difficulty reading, recognizing faces), Gray or black spots in the center of the visual field, Sensitivity to bright light (photophobia), Difficulty adapting from bright to dim environments (delayed dark adaptation), Color vision changes, particularly difficulty distinguishing blues and yellows, among others. Approximately 1 in 8,000 to 10,000 people; an estimated 30,000 affected individuals in the U.S.. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Stargardt Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Stargardt disease has no FDA-approved therapy, but the clinical trial pipeline is one of the most active in inherited retinal disease. Gene therapy approaches using dual-vector AAV systems (the ABCA4 gene is too large for a single AAV vector) are in Phase 1/2 trials.

As of October 14, 2026, no current FDA drug label names Stargardt Disease as a condition the drug treats. The FDA is due to decide on Tinlarebant by February 12, 2027; the FDA calendar page carries the outcome the day it lands.

Stargardt Disease is caused by variants in the ABCA4 and ELOVL4 genes. Most cases are biallelic ABCA4 variants (STGD1).

It follows autosomal recessive (ABCA4) or autosomal dominant (ELOVL4) inheritance. Approximately 1 in 8,000 to 10,000 people; an estimated 30,000 affected individuals in the U.S. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Stargardt Disease looks at the ABCA4 and ELOVL4 genes. Most cases are biallelic ABCA4 variants (STGD1).

It follows autosomal recessive (ABCA4) or autosomal dominant (ELOVL4) inheritance.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Stargardt Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Stargardt Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.